PharmaMar Cierra un Mes de Marzo de Infarto ... ¿ Va Hacia la Media de 200 Sesiones en los 72 € ? ...

 

PHARMAMAR . Posible Riesgo :

La Mayor Presión Competitiva en el Sector del SMALL CELL LUNG CÁNCER Debido a la Llegada de Nuevos Participantes Podría Limitar la Oportunidad de Crecimiento de Lurbinectedin , lo Que Podría Afectar la Cuota de Mercado y los Ingresos.

BLACKROCK COMPRA EN LAS CAÍDAS DE IAG ..//.. IAG ESTA COMPRANDO ACCIONES DE IAG EN LA CAÍDA TAMBIEN ... ENTONCES TODOS CONTENTOS ... ¡ MUERTA IA SUEGRA, VIVA LA PEPA ! . CÓNDOR ¿ La Aerolínea Alemana, el 'Plan C' de IAG Para Consolidarse en Europa ?.

 

NATIONAL LIBRARY OF MEDECINE // JAMA NETWORK : SMALL CELL LUNG CÁNCER EXTENSIVE-STAGE EN SEGUNDA LINEA . LURBINECTEDIN CONSIGUE UNA TASA DE RESPUESTA GLOBAL ( ORR ) DEL 35 % ... UNA MEDIANA DE SUPERVIVENCIA LIBRE DE PROGRESIÓN ( PFS ) DE 3,7 MESES Y UNA MEDIA DE OVERALL SURVIVAL ( OS ) DE 9,3 MESES ///. TARLATAMAB CONSIGUE UNA TASA DE RESPUESTA GLOBAL ( ORR ) DEL 40 % . UNA MEDIANA DE SUPERVIVENCIA LIBRE DE PROGRESIÓN ( PFS ) DE 4,9 MESES Y UNA MEDIA DE OVERALL SURVIVAL ( OS ) DE 14,3 MESES .

 

JAMA NETWORK, March 31, 2025 .

Small Cell Lung Cancer A Review .
So Yeon Kim, MD , Henry S. Park, MD, MPH ; Anne C. Chiang, MD, PhD . ... YALE UNIVERSITY SCHOOL OF MEDICINE, NEW HAVEN , CONNECTICUT .

SECOND-LINE THERAPY FOR PATIENTS WITH ES-SCLC INCLUDES :

THE DNA-ALKYLATING AGENT LURBINECTEDIN :

*.- 35% OVERALL RESPONSE RATE .

*.- MEDIAN PROGRESSION-FREE SURVIVAL ( PFS ) , 3.7 MONTHS ) .

*.- MEDIAN OVERALL SURVIVAL ( OS ) : 9,3 MONTHS ...

... AND A BISPECIFIC T-CELL ENGAGER AGAINST DELTA-LIKE LIGAND 3 , TARLATAMAB :

*.- 40% OVERALL RESPONSE RATE .

*.-  MEDIAN PROGRESSION-FREE SURVIVAL ( PFS ) , 4.9 MONTHS ) .

*.- MEDIAN OVERALL SURVIVAL ( OS ) :  14,3 MONTHS ...

TARLATAMAB - DLL3 : A Beginning For Bispecific Therapies in Small Cell Lung Cancer ...//... TARLATAMAB - Dlle : UN COMIENZO PARA LAS TERAPIAS BIESPECÍFICAS EN EL SMALL CELL LUNG CÁNCER - ES .

Las Nuevas Pautas del National Comprehensive Cáncer Network Recomiendan TARLATAMAB Como una Opción de SEGUNDA LÍNEA Para el SMALL CELL LUNG CÁNCER en Etapa Extensiva ( ES )  Sensible y Resistente al PLATINO Debido a su Respuesta Duradera y su Perfil de Seguridad .

SECOND LINE An Later Treatment Options For SMALL CELLS LUNG CÁNCER ARE LIMITED .

 
TARLATAMAB Offers a New Approach to SMALL CELL LUNG CÁNCER THERAPY , Demonstrating Long-Lasting Responses and Tolerable Adverse Effects in Pretreated Patients .

SMALL CELL LUNG CÁNCER (SCLC) is a highly proliferative malignancy and the most aggressive type of lung cancer, accounting for 15% of bronchogenic carcinomas worldwide .

 Although the overall incidence of and mortality rate for SCLC have decreased over the last several decades, the 5-year survival rate continues to be poor, at less than 10% .

SCLC is known to be responsive to chemotherapy and radiotherapy, but more recent developments indicate that it is also responsive to immunotherapy, although less so than other types of cancer .

Patients with SCLC treated with platinum-based therapy in the first-line setting may be retreated with platinum-based therapy if the platinum-free interval has been more than 6 months ; those with SCLC who are platinum resistant may be treated with agents such as LURBINECTEDIN ( ZEPZELCA; JAZZ PHARMACEUTICALS, Inc ), which has demonstrated a response rate of 35.2% or greater depending on the chemotherapy-free interval but a short duration of response (DOR; median, 5.3 months) .

Because the historical standard of care for SCLC ( ie, chemoimmunotherapy ) produces high initial response rates that are short-lived—particularly for extensive-stage SCLC—there remains an unmet need for more effective treatment options with durable responses, particularly once initial therapy has failed .

In May 2024, the FDA Granted Accelerated APPROVAL To TARLATAMAB - DLL3 ( IMDELLTRA; AMGEN Inc ) for the Treatment of adult patients with extensive-stage SCLC with disease progression on or after at least 1 Platinum-based chemotherapy .

 The APPROVAL was based on the agent demonstrating long-lasting responses in pretreated patients and made TARLATAMAB the first bispecific T-cell engager therapy for SCLC . ...